INDEX

A

A Mind That Found Itself, 93
Abuse, 229-234, 250, 251, 254-256, 286-289, 335, 340, 342, 368-370, 427-430, 445-449, 455
Acetylcholine, 36, 252, 361, 362
Acetylcholinesterace (AchE), 362
Acute stress disorder, 233, 237
Addictive disorders, 17, 23, 36, 46, 48, 126, 193, 244, 408
Administration on Aging, 370, 371
Adolescent Antisocial Self Report Behavior Checklist, 139
Adult day centers, 363, 371–374, 380
Adverse selection, 20, 420, 423, 426, 429
Agency for Health Care Policy and Research, 263, 280, 424
Aging, 19, 335–341, 344, 345, 348, 349, 357, 360, 361, 368–372, 374–376, 379, 381
Agoraphobia, 47, 48, 161, 228, 233–235, 239, 336
Air Force Surgeon General, 160
Akathisia, 89, 281, 344
Alcohol. See Substance abuse
Alcohol and Drug Abuse and Mental Health Administration Reorganization Act of 1992. See Public Law 102321
Alcoholics Anonymous, 94, 289
Alprazolam, 242, 355
Alzheimer’s disease, 356–364
acetylcholinesterase (AChE) inhibitors, 362
assessment and diagnosis of, 357–360
caregivers, 363–364
causes, acetylcholine and, 361–362
causes, biological factors, 360–361
causes, histopathology and pathophysiology, 361
causes of, 360–362
causes, protective factors, 360–361
cost of, 360
course of, 359
diagnosis and prevention of progression.
357, 358
gender and, 359
graying of America and, 360
memory aids, 363
mild cognitive impairment (MCI), 357–359
prevalence and incidence of, 359–360
primary care providers, 358
societal view of senility, 358
symptoms of, 356, 359
treatment of behavioral symptoms, 362–363
treatment, cognitive and behavioral, 363
treatment of depression, 363
treatment, in nursing homes, 364
treatment, pharmacological, 362–363
treatment, psychosocial, of patients and caregivers, 363–364
American Academy of Child and Adolescent Psychiatry (AACAP), 146, 158
American Academy of Pediatrics, 149, 183
American Association of Retired Persons, 370
American Medical Association (AMA), 438
American Psychological Association (APA), 11, 71, 91, 140, 147, 155, 162, 166, 438, 445
American Psychological Association Task Force Criteria, 140, 155, 162, 166
Americans With Disabilities Act (ADA), 285, 446, 447
Amino acids, 36, 37
Amnesia, 237
Amphetamine salts, 146
Amphetamines, 158
Amygdala, 36, 38, 239, 240

467
Mental Health: A Report of the Surgeon General

Anhedonia, 41, 42, 245, 271
Anorexia nervosa, 47, 48, 53, 136, 167, 228, 336
Anthony, William, 100
Anticonvulsants, 69, 260, 266, 268
Antidepressants, 261-266, 352-355
Antioxidants, 361
Anxiety, 40-41
animal model of, 52
anxiety disorder defined, 40
causes and onset of, 40
depression and, 253-54
Anxiety disorders in adults, 225-226, 233-243
acute and post-traumatic stress disorders, 237
acute stress response and the brain, 238-239
agoraphobia, 234-235
anatomic and biochemical bases of, 239-240
causes of, 239-241
combined psychotherapy and pharmacotherapy, 242
counseling and psychotherapy for, 241, 243
generalized anxiety disorder, 235-236
neurotransmitter alterations, 240
obsessive-compulsive disorder, 236-237
occurrence and co-occurrences, 233
panic attack and panic disorder, 233-234
pharmacotherapy for, 242-243
psychological theories of, 240-241
social phobia, 235
specific phobias, 235
stressor and stress response defined, 238
treatment of, 241-243
types of, 233-237
Anxiety disorders in children and adolescents, 160-163
CBT and, 162
generalized anxiety disorder, 160
obsessive-compulsive disorder and PANDAS, 162-163
separation anxiety disorder, 160-161
social phobia, 160-161
treatment of, 162
Anxiety disorders in older adults, 364-365
benzodiazepines and, 364-365
buspirone and, 365
post-traumatic stress disorder (PTSD), 364
prevalence of, 364
treatment of, 364-365
Anxiolytics, 69, 71, 242, 243, 365
Asian, 81-83, 85-88, 182, 282, 289
Asian/Pacific Islanders, 81-83, 85-88, 182, 242, 263, 282, 289
Aspartate, 37
Asperger's disorder, 137
Assault, 87, 161, 230, 237
Asserative community treatment, 80, 92, 99, 227, 280, 286, 287, 290, 295, 455
Attachment, 60, 126, 126, 130-132, 165, 254
Attention deficit/hyperactivity disorder (ADHD), 142-150
associated disorders and, 144
causes of, 144-145
dopamine hypothesis, 145
inheritance, 145
MTA Study, 148-149
prevalence of, 144
psychostimulants, 146
symptoms of, 147-144
treatment, behavioral, 147-148
treatment, CBT, 148
treatment controversies, 149-150
treatment, multimodal, 148-149
treatment of, 146-150
treatment, pharmacological, 146-147
treatment, psychosocial, 147-148
treatment side effects, 146-147
Attrition factors, 258, 263, 356
Atypical antipsychotics, 69, 345
Auditory hallucinations, 41, 150, 271
Index

Autism, 23, 53, 129, 136, 137, 163, 164
Autistic disorder, 270
Avoidance, 6, 41, 82, 161, 229, 234, 235, 237, 240, 254, 255, 273, 343
Axons, 33, 37, 58
Azopyrine, 243

B
Baby boomers, 368, 369
Bandura, 57, 126, 162, 229
Basal ganglia, 35, 55, 163
Bazelon Center for Mental Health Law, 80
Beers, 93
Behavior therapy, 57, 66, 67, 149, 162–164
Benzodiazepines, 69, 142, 162, 242, 243, 268, 343, 350, 364, 365, 369, 370
Biological models of the mind, 39
Biopsychosocial model of disease, 52
Bipolar disorder, 250, 266. See also Mania
Blame, 96, 154, 158, 164, 187, 274
Bowlby, John, 57, 59, 60, 126
Boys Town, 177
Brain, 6, 13, 15–17, 239–241, 453
anxiety disorders and, 238–240
bottomup studies of, 13
cellular changes in, as result of human experience, 15
as central focus for studies of mental health and illness, 13
genes, role of, 13, 16–17
inseparability of human experience, 15
as mediator of mental function, 13
as mediator of symptoms of mental illness, 453
mental disorders and physical changes in, 6
physical changes in as cause of changes in body, 6
prenatal factors, 16
topdown research, 13
Brain damage, 129, 145
Brain, imaging of, 38–39
Brain, neurochemical complexity of, 36–37
aspartate, 37
corticotropin-releasing factor (CRF), 36
dopamine, 36, 37
endogenous opiates, 36
gamma amino butyric acid (GABA), 37
glutamate, 37
ligand-gated channel, 36–37
neurotransmitter receptor, 36
neurotransmitters, 36–37
neurotransmitters as targets of medication, 37
norepinephrine, 37
peptides, 37
serotonin, 37
substance P, 36
Brain, plasticity of, 12, 38
brain structure altered with learning, 38
dual-level examination necessary, 38
genes and, 38
molecular and cellular alterations, 38
as result of stress, substance abuse, and disease, 38
Brain, structural complexity of, 32–37
amygdala, 36
axons, 33, 35
basal ganglia, 35–36
cellular level organization, 32–36
cerebral cortex, 33
as distributed information processor, 33
frontal lobe, 33
geographic specialization, 33–36
gray matter, 35
gyri, 33
hippocampus, 36
local damage compensated by other regions, 36
as mediator of all human behavior, 31
and mind, 31
myelin, 33–35
organization of circuits in, 33
occipital lobe, 33
parietal lobe, 33
prefrontal cortex, 33
sulci, 33
white matter, 33–35
Bruner, Jerome, 126, 133
Bupropion, 147, 263, 264, 266, 267, 353
Buspirone, 242, 243, 244, 365

C
California Department of Mental Health, 99
Call to Action on Suicide, 4, 244
Campbell, 95, 99, 134, 141, 157, 164, 166, 439, 442, 443
Cancer diagnosis, reaction to, 52
Carbamazepine, 142, 157, 166, 268
Cardiotoxicity, 263
Carolina Abecedarian Project, 134
Carved-in, carved-out benefits, 376–377, 421
Case, definition of, 48
Case manager, 94, 95, 173, 174
Catatonia, 249, 259, 261
Causation, 10, 44, 50–52
Causation, difficulty in establishing, 51–52
Center for Mental Health Services (CMHS), 24, 80, 82, 90, 95, 107, 186, 188, 189, 261, 273, 286, 290, 290, 294, 295, 425
Center for Substance Abuse Treatment, 446
Centers for Disease Control and Prevention, 62, 159
Central nervous system, 42, 61, 129, 145, 163, 251, 278, 338, 353
Cerebral cortex, 33, 238
Chamberlin, Judi, 93–94
CHAMPUS, 192
Child abuse, 130, 132, 135, 445, 446. See also Abuse
Child sexual abuse, 231
Children and adolescents, in general, 17–18, 123–194
Children and adolescents, mental disorders in, 123, 136–142
anxiety disorders in See Anxiety disorders in children and adolescents
assessment and difficulty of diagnosis in, 137–138
attention deficit/hyperactivity disorder, 142–150, 164
autism, 163–164
disruptive disorders, 164–166
eating disorders, 167
evaluation process, 138–139
general categories, 136–137
medications, off label use of, 141
oppositional defiant disorder (ODD), 164–165
psychopharmacology, and lack of research on medications, 140–142
psychotherapy, and lack of evidence concerning efficacy, 140
shortage of professionals, 138
substance use disorders in adolescents, 166–167
treatment strategies, 139–142
Child and Adolescent Service System Program (CASSP), 188, 189, 192
Child Behavior Checklist, 139
Child Health Insurance Program (CHIP), 183, 407, 419
Children and adolescents, 12, 16–18, 46, 48, 90, 103, 247, 250, 406, 409, 455, 457
Children and Adults with Attention Deficit Disorder (CHADD), 148
Children and Youth Intensive Case Management (CYICM), 173
Children’s Services Program, 189, 191
Chlorpromazine, 68, 157, 278, 280
Cholecystokinin, 240
Chronic disability, 337
Classical conditioning, 56, 240
Clinical Global Improvement Scale, 156, 157
Clinical psychologist, 138
Clinical research volunteers, 21, 454
Clinician bias, 85, 87, 88, 273, 288
  overdiagnosis of schizophrenia in African Americans, 88
  underdiagnoses, 88
Clomipramine, 164, 242
Clonazepam, 242
Clonidine, 147, 166
Clozapine, 268, 278, 280–282, 345, 367
Code of Ethics, 438
Coercion, 23, 457
Cognitive capacity, 337
Cognitive decline, 341, 358
Cognitive therapy, 355, 363
Combined services and combined treatment, 18–19, 288–289, 296, 412–413
Community-based interventions, newer, 172
Community Support Program, 290, 295
Community treatment, 79, 80, 92, 99, 227, 280, 286, 287, 290, 295, 455
Comorbid medical illness, 273
  and depression, 244
  and schizophrenia, 273–274
Comorbidity, 46, 47, 63, 72, 166, 167, 228, 233, 234, 244, 267, 273, 288, 338, 340, 342, 346, 352, 354, 360, 372, 377, 406, 408
Comprehensive care, 225, 289
Conduct disorder, 126, 130–132, 137, 150–152, 164–166, 171, 189
Confidentiality, 13, 20, 21, 438, 440, 447–449
Confidentiality: ethical, legal, and policy issues, 437–449
  case utilization review and candor, 440
  ethical issues, 438–439
  fostering trust, 439
  industry changes, and for profit corporations, 437
  more protections may be warranted, 437
  protecting privacy, 439–440
  reducing stigma, 439
  research on confidentiality and treatment, 440–441
  technological advances in information usage and storage, 437
  values underlying confidentiality, 439–440
Confidentiality of Individually Identifiable Health Information, 447
Confidentiality law, 440–448
  differs for mental health and substance abuse treatments, 448
  disclosure, 443–445
  disclosure to client, and child clients, 443
  exceptions to confidentiality, 442–445
  national standard lacking, 441
  preemption, 447–448
  reform proposals, 441–442
  in research, 444–445
  valid consent rarely defined, 442
  waiver of confidentiality, 442
Confidentiality of mental health information, 20–21, 437–449
  information technology and, 21
  informed consent and, 21
  state and Federal laws and, 21
  U.S. Supreme Court and, 21
Confusional state, 249
Consent, 21, 72, 260, 261, 440, 442–449
Consumer advocacy, 291–293
Consumer and family, 13, 14, 92, 96–98, 100, 101
Consumer and family movements, 92–97
  blame attributed to families and, 96
  consumer groups, origins and goals, 93–94
  consumer organizations, accomplishments of, 95–96
  consumer roles in research, 95–96
  consumers as employees, 95
  deinstitutionalization and, 96
  family advocacy, 96
Mental Health: A Report of the Surgeon General

Federation of Families for Children’s Mental Health (FFCMH), 96–97
incorporation into other mental health services, 94
National Alliance for the Mentally Ill (NAMI), 96
National Mental Health Association (NMHA), 96–97
Public Law 102-321 and, 95
self-help groups, 94
underrepresentation of ethnic and minority groups in, 93–94
Consumer Bill of Rights and Responsibilities, 20, 430, 429
Consumer run, 15, 94, 102, 290
Contingency management, 147, 162
Control group, 10, 71, 134, 148, 155, 156, 164, 172, 174, 175, 191, 233
Co-occurring mental and substance use disorders
combined treatment of, 18–19, 288–289, 296, 412–413
comorbidities, 244
in adolescents, 166–167
in older adults, 368–370
incidence of, 15, 46
long-term outcome, 288
post-traumatic stress disorder and, 237
schizophrenia and, 273–274
shortage of services for, 455
Coping and self-monitoring, 284
Correlation, 51, 165
Correlational research, 10, 51
Corticotropin-releasing factor (CRF), 36
Corticotropin-releasing hormone (CRH), 36, 239, 240, 242, 253
Cortisol, 153
Cost containment, 20, 408, 417, 419, 421, 429, 437
Cost controls, 423
Counseling, 138, 149, 156, 159, 169, 175, 182, 183, 189, 232, 241, 265, 269, 294, 342, 343, 364, 373, 406, 437
Couples therapy, 65, 232
Crisis programs, 178
Crisis services, 12, 16, 94, 102, 159, 172, 178–179, 288, 290
Cultural diversity and mental health services, 45, 55, 80
acculturation, defined, 81
Americans and, 88
barriers to treatment of minorities, 86-88
clinician bias, 88
coping and idioms of distress, 83
coping and religious beliefs, 82–83
coping and somatization and folk disorders, 83
coping styles of various cultural groups, 82–83
cost, 87–88
cultural competence, defined, 90
cultural competence in mental health practitioners, 90–91
culture and cultural identity, 81–82
diversity and demographics, 81–83
DSM-IV “Outline for Cultural Formulation,” 90
epidemiology and utilization of services, 84
ethnopsychopharmacology, 88–89
family and community as primary resources, 83–85
improving treatment for minority groups, 88–91
income status and role in mental disorders, 82
Indian Health Service (IHS), 90
linguistically and culturally competent services, 81, 225
metabolism, genetic and psychosocial influences, 89
minorities, fear of system by, 80–81
minorities poorly served, 80–81
minority-oriented services, 89–90
mistrust, 86–87
overdiagnosis of schizophrenia in African Americans, 88
racial or ethnic minority groups, major, Federal designation, 81
racist slights, microinsults, 87
rural mental health services, 92
stigma, 87

treatment effectiveness across race, culture, largely unknown, 91

underdiagnoses, 88

under- and overrepresentations in treatment populations, 84–86

unrecognized variations in health-seeking behaviors, 84

Culturally appropriate treatment, 18, 49, 84, 90, 181, 182, 186,

Cyclothymia, 226, 244, 245, 251

Cystic fibrosis, 53

D

Darwin, 60

DAT, 1, 145

Deegan, 97, 98

Deinstitutionalization, 7, 8, 68, 79, 93, 96, 98, 275, 286, 293, 374, 405. See also Institutionalization and deinstitutionalization

Delirium, 9, 338, 358

Delivery of state-of-the-art treatments, 22, 455


Demographic characteristics, 405

Dendrites, 33, 61

Department of Health and Human Services, 23, 232, 370, 413, 447

Depression and other mood disorders in adults, 226, 228, 244–269

acute inpatient treatment, 258

acute phase efficacy in mania, 267–268

anxiety and depression, 253

assessment, 245–251

augmentation strategies, 265

biological factors in, 251–252

bipolar depression, treatment of, 265–266

bipolar disorder, 246, 249, 250

bupropion, 264

causes, 251–257

clinical depression, 244–246

cognitive factors, 254–255

complications and comorbidities, 244–245

continuation phase therapy, 261

cyclothymia, 250–251

diagnosis and syndrome severity, 245–251

dysthymia, 247, 249

electroconvulsive therapy (ECT), 258–261

evolving views of, 252–253

female depression, role of environment in, 255–256

gender and, 255–256

heterocyclic antidepressants (HCAs), 262

hippocampus and, 253

learned helplessness, 254–255

maintenance pharmacotherapy vs. psychotherapy, 267

maintenance phase therapies, 261

maintenance treatment in mania, 268

major depressive disorder, 247–248

medication, contributing role in, 251

misdiagnosis of schizophrenia in African Americans, 249

monoamine hypothesis, 252

monoamine oxidase inhibitors (MAOIs), 262, 264

outpatient treatment, 258

pharmacotherapies, 262–263

pharmacotherapies, alternate, 263–265

pharmacotherapy, psychosocial therapy, and multimodal therapy, 266–267

and primary care, 269

psychosocial and genetic factors in, 254–257

psychotherapy and counseling, 265

relapse, prevention of, 267

remission defined, 261

selective serotonin reuptake inhibitors (SSRIs), 262–263, 265

service delivery for, 269

social and economic impact, 244

St. John's wort, 264–265

stressful life events, 254

suicide, 244, 245

temperament and personality, 255

therapy, stages of, 257–261

treatment, general, 257–262
Index

Education, 93–97, 126, 133–136, 183–185, 187–189
Effectiveness and efficacy, 3, 10, 11, 13–15, 21, 22, 65, 67, 71, 72, 91, 94, 101, 102, 416, 418, 453
Ego, 56, 60, 338
Ego integrity, 60, 338
Electroconvulsive therapy (ECT), 65, 93, 94, 250, 258–262, 266–268, 354, 355
Elmira Prenatal/Early Infancy Project, 134
Employers, 74, 289–294, 294, 377, 407, 418, 421
Empowerment, 95, 99, 188, 289, 293
Empowerment Scale, 99
Endocrine factors, 255, 340
Endogenous opiates, 36
Engel, George L., 50
Epidemiologic Catchment Area (ECA), 46–48, 228, 257, 336, 341, 348, 349, 364, 369, 406, 408
Epidemiology, future directions for
mental disorder, case of, defined, 48
mental disorder, establishing threshold for, 48–49
rates of disorder vs. measures of need, 49
treatment, lack of standard measures of need for, 49
Epigenetic influences, 58
Erikson, Erik, 57, 59, 60, 126, 227, 338
Estrogen, 275, 342, 361, 367
Ethical Principles of Psychologists, 438, 439
Ethnicity, 80–84, 91, 181, 182, 262, 282
Ethnopharmacology, 282
Ethnopsychopharmacology, 88–89
Etiology of mental disorders, 31, 49–57
and age, 51
biopsychosocial factors in, 50, 52
correlation, causation, and consequences, 51–52
defined, 31
of extroversion, 50
interplay of factors in, 49
of post-traumatic stress disorder, 50–51
and stress, 51, 52
stressor, defined, 51
stress response, defined, 51
Etiology research, 11, 31, 341
Evidence-based interventions, 21, 454
Evidence-based services, 22, 455
Excess disability, 341, 343, 351, 358
Experimental group, 10, 164, 174
Experimental research, 10, 51
Extra Organizational Empowerment Scale, 99
Eyberg Child Behavior Inventory, 139

F
Family advocacy, 96, 98, 292
Family Centered Intensive Case Management (FCICM) program, 174
Family Interaction Coding Pattern, 139
Family intervention, 158, 283
Family preservation programs, 175
Family support, 22, 96, 178, 188, 189, 274, 278, 364, 370, 375, 380, 455
Family therapy, 155, 157, 167, 168, 189
FDA Modernization Act, 141
Fear and anxiety, 31, 36, 40, 52, 233–235, 238–240, 241
Fear of mental health system by minority groups, 80–81, 87
Federal Employees Health Benefit Program, 429, 458
Federal financing, 376, 420
Federal government, role of, in mental health issues, 81, 188, 375, 407, 415, 420, 426, 438, 447
Federation of Families for Children’s Mental Health (FFCMH), 80, 96, 97, 188, 189
Fetal alcohol syndrome, 133, 163
Financial barriers, 20, 23, 257, 429, 457
Fluoxetine, 147, 156, 164, 243, 262, 263, 353
Flupenthixol, 158
Fluvoxamine, 243, 262
Food and Drug Administration (FDA), 10, 11, 70, 71, 141, 243, 262, 263, 268
Fort Bragg study, 191, 193
Fostering Individualized Assistance Program (FIAP), 174
Freud, Anna, 127
Mental Health: A Report of the Surgeon General

Freud, Sigmund, 55, 59, 66, 124, 126, 127
Frontal lobe, 33, 354, 357
Future directions for epidemiology, 48

G
G protein-linked receptors, 37
Galton, 60
Gamma amino butyric acid (GABA), 37, 240, 242, 252
Gatekeepers, 138
Gender, 12, 14, 16, 19, 22, 39, 44, 55, 63, 81, 86, 101, 102, 153, 159, 171, 228, 235, 244, 255, 256, 263, 275, 282, 359, 426, 456. See also Alzheimer's disease; Depression and other mood disorders in adults; Depression and suicide in children and adolescents; Schizophrenia, demographic characteristics in; Schizophrenia in older adults
General medical service providers, 413
Generalized anxiety disorder, 40, 47, 137, 160, 161, 225, 228, 233–236, 239, 242, 243, 364
Genetic factors, 50, 127, 153, 163, 226, 237, 251, 254, 256, 276, 360
Genetics, 11, 13, 21, 39, 52, 53, 100, 129, 144, 257, 279, 453
Gestalt therapy, 67
Glia, 32
Global Burden of Disease study, 4, 411
Glucocorticoids, 239, 240, 251
Glutamate, 36, 37
Glycine, 36, 37
Gray matter, 35, 36, 239
Grief, 66, 230, 245, 254, 265, 340, 342, 351, 356
Grob, Gerald, 6, 9, 75, 78, 93
Group therapy, 65, 177, 231
Guanfacine, 147
Gyri, 33

H
Haloperidol, 69, 164, 280, 281, 367
Harvard University, 4
Head Start, 133, 134
Health Care Financing Administration (HCFA), 45, 412, 416
Health insurance, 20, 182–185, 294, 418–421, 422, 427, 438, 457
Health insurance benefits, 70, 79, 232, 292, 407, 426–428, 455, 457
Health maintenance organization (HMO), 374, 376, 421, 422
Health Security Act, 427
Heart, 147, 238, 263, 268, 352, 355
Heterocyclic antidepressants (HCAs), 262
Hippocampus, 36, 38, 61, 239, 240, 252, 253
Hispanic Americans, 81, 85, 86, 152, 181, 186–187, 256, 282, 289, 368
Histopathology, 361
HIV, 54, 55, 62, 133, 251, 286, 288, 357
Home Based Crisis Intervention (HBCI), 179
Home-based services, 74, 140, 166, 172, 175
Homicide, 244
Human genome project, 52, 53
Humanistic approaches, 65–67
Huntington's disease, 53, 357
Hypersonmia, 42, 24/
Hyperthyroidism, 234, 250
Hypomania, 151, 153, 249, 250, 251, 266, 348
Hypothalamic-pituitary-adrenocortical (HPA) axis, 239, 252, 253
Hypothalamus, 153, 239, 253
Hypothyroidism, 247, 251, 256, 338, 357, 358

I
Id, 56
Illicit drugs, 368, 369
Imipramine, 68, 69, 156, 157, 242, 267, 362
Immune function, 337, 340
Impulsivity, 142–144, 146, 148, 229, 255
Income assistance, 292
Indemnity, 419, 421
Indian Health Service (IHS), 90
Individuals With Disabilities Education Act (IDEA), 183, 184, 188, 189
Inequities in treatment and services, 13, 20, 405, 413, 426-429, 457
Infancy, 44, 99, 131, 134, 135, 342
Infant Health and Development Program, 134
Infections, 52, 133, 163, 251, 278
Informed consent, 21, 72, 260, 261, 440, 449
Inpatient treatment, 88, 169, 171, 172, 175, 176, 258, 456
Institutionalization and deinstitutionalization, 68, 75, 78–79, 84, 93, 96, 98
Insurance restriction, 426
International Classification of Diseases (ICD), 45, 83
Interneuron, 32
Interpersonal therapy, 22, 66, 125, 155, 157, 167, 261, 265–267, 353, 355–356, 455
Intervention, 152–156, 140, 155–159, 162, 164–166, 177–180, 190–192, 231, 244, 260
Invisible Children, 97
Invisible Children's Project, 184
Involuntary commitment, 23, 93, 457
IQ, 133, 134, 165, 171, 337

J

Jackson, 84

K

Kandel, 6, 57, 58, 61, 138, 240
Kaslow and Thomson, 156
Kierkegaard, 67
Knitzer, 97, 171, 187

Kraemer, 129
Kraepelin, 97, 269, 366

L

Landscape for aging, 371, 372
Language, 5, 6, 43, 50, 62, 81, 86, 124, 126, 136–138, 149, 163, 164, 269, 271, 337, 356, 357, 359, 437, 439, 441
Late onset of mental disorders, 244, 347, 350–352
Late-onset depression, 347, 350–352
Law enforcement, 133, 191, 445, 446
Learned helplessness, 254
Lethality, 263
Level of evidence, 10, 11, 142, 159
Lewinsohn, 152, 154, 156
Lifespan, 15, 102
Lifespan approach, 12
Ligand, 36
Limbic system, 37
Lithium, 68, 69, 142, 147, 157, 158, 166, 249, 260, 265–268
Living With Children, 166
Locus coeruleus, 37
Lorazepam, 242
Lorenz, Konrad, 60

M

Madness Network News, 93
Magnetic Resonance Imaging (MRI), 14, 38, 100, 240, 347, 351
Maintenance pharmacotherapy, 261, 267
Malpractice, 266
Managed behavioral health care organizations (MBHOs), 421
Managed care, 13, 19, 20, 23, 85, 94, 169, 181, 183–185, 268, 282, 290, 336, 370, 371,
Mental Health: A Report of the Surgeon General

373, 375-378, 405, 417, 420-430, 443, 455, 458
Managed Care Consortium, 291
Mania, 42, 43, 69, 151, 157, 244-246, 249, 251, 252, 258-261, 266-268, 348
Mann, Horace, 78, 153, 246
MECA Study, 124
Memory, 31, 33, 36, 38, 337-338, 341, 355-359, 362-367
Mendelian disorders, 53
Mendelian transmission, 53
Menninger Clinic, 177
Mental disorders, 4-5, 20, 39-40
brain as mediator in, 39
characterized by, 39
continuum of conditions, 39
cost to the Nation, 20
cultural influence and, 39
defined, 5
demographics and, 39
prevalence of, 20
prevention of, 233
societal burden compared, 3-4
Mental health, 3-6
defined, 4-5, 227
dynamic and ever changing, 16
inseparable from physical health, 5-6
success dependent on, 4-5
vs. somatic health, 6
Mental health and mental illness
biological influences on, 52-55
brain and scientific research, 100
causes of, 225
consumer and family movements, 101-102
integrative science of, 57
Kandel and, 57
lifespan and, 102-104
organization and financing of care, 101
personality traits, 227-230
psychosocial influences on, 55-57
treatments and integrative neuroscience, 100-101
Mental Health Parity Act, 427, 428
Mental health promotion and illness prevention, 22, 454
Mental illness
in children and adolescents, 46, 48
cluster of signs and symptoms and, 45
co-occurring disorders in adults, 46
cost to the individual, 227
cost to society, 226
costs, 49, 225-227, 411-417
diagnosis of, 43-45
disorder vs. disease, 44
epidemiology, defined, 45
epidemiology of, 45-49
in older adults, 48
incidence, defined, 45
inseparable from physical illness, 5-6
prevalence, defined, 45
serious emotional disturbance (SED) in children and adolescents, 46
serious mental illness (SMI) in adults, 46
severe and persistent mental illness (SPMI) in adults, 46
symptoms and signs of, 39-40
Mental retardation, 23, 130
Meta-analysis, 11, 167, 168, 175, 266, 355
Metabolism, 88, 89, 154, 238, 263, 265, 277, 280, 283, 342, 344
Methodology for Epidemiology of Mental Disorders in Children and Adolescents (MECA) study, 48, 123, 124
Methylphenidate, 145-147, 149, 150, 157, 166
Mild cognitive impairment (MCI), 357, 358
Millon Adolescent Personality Inventory (MAPI), 138
Mini Mental Status Exam, 359
Minnesota Multiphasic Personality Inventory (MMPI), 139
Minority groups, 23, 31, 45, 73, 80-84, 86-88, 90, 186, 233, 257, 289, 456. See also African Americans: Asian/Pacific Islanders; Hispanic Americans; Native Americans/American Indians/Alaska
Index

N

Naltrexone, 370
National Advisory Mental Health Council (NAMHC), 46, 424, 428, 436
National Alliance for the Mentally Ill (NAMI), 80, 96, 188, 189, 292, 428, 438
National Association of Mental Patients, 94
National Comorbidity Survey (NCS), 46, 47, 167, 228, 364, 406, 408
National Household Survey on Drug Abuse, 369
National Institute of Mental Health (NIMH), 24, 32, 52, 53, 54, 61, 84, 95, 129, 190, 139, 146, 148, 157, 163, 237, 251, 255, 257, 259, 260, 280, 290, 342 354, 409
National Institutes of Health (NIH), 24, 71, 144, 259, 260, 340, 341, 346, 348, 349, 354
National Mental Health Association (NMHA), 78–80, 93, 96, 97, 133, 183, 189, 291
National Mental Health Consumers’ Association, 94
National Research Council, 181, 232
Native Americans, 86, 90, 288
Native Americans/American Indians/Alaska Natives/Native Hawaiians (American Indians), 81, 86, 87, 90, 153, 191, 288
Naturalistic studies, 354

Nature and nurture, 12, 60, 61, 136
Nefazodone, 243, 263, 267, 353
Negative reinforcement, 56, 240
Nerve cells, 13, 32, 33, 37, 100
Neurobiology, 238
Neurocircuits, 239
Neurodevelopmental disruption, 276
Neurodevelopmental theory of schizophrenia, 278
Neuroendocrine systems, 61, 153
Neuroimaging, 239, 240, 252, 357
Neuroleptic, 68, 69, 147, 158, 268, 272, 344, 345, 366, 367
Neuronal activity, 33
Neurons, 13, 32–38, 50, 54, 55, 58, 61, 68, 100, 163, 238, 242, 252, 253, 262, 361, 362
Neuroscience of mental health, 31, 32
Neuroticism, 229, 255
Neurotransmitter receptors, 33, 36–38, 50, 68–70, 262–263, 277, 280
Neurotransmitters, 33, 36, 37, 68, 239, 240, 252, 361
NIMH Diagnostic Interview, 139
Norepinephrine, 36, 37, 70, 238–240, 252, 263, 264
Nortriptyline, 353, 354, 356
Nursing, 365, 370–372, 374–376, 406, 413, 417

O

Obsessive-compulsive disorder (OCD), 55, 236–237
relationship to anxiety, 40–41
Occipital lobe, 33
Off-label usage, 141, 262
Office of the Surgeon General, 23, 342
Older adults
alcohol and substance use disorders in, 368–370
anxiety disorders in, See Anxiety disorders in older adults
assessment and diagnosis, 340–341
demographics of the near future, and, 19
depression and suicide in, See Depression and mood disorders in older adults
interventions for, 19
mental disorders in, 19; 340–346
prevention, 341–343
prevention of depression and suicide, 342
prevention of excess disability, 343
prevention of premature institutionalization, 343
primary care, 341
primary prevention, 342
schizophrenia. See schizophrenia in older adults
treatment for mental disorders, 343–346
Older adults and mental health, 336–340
change and human potential, 338–339
cognitive capacity, 337–338
coping with loss and bereavement, 339–340
normal life-cycle tasks, 337
Omnibus Budget Reconciliation Act, 364, 374, 375
On Our Own, 93
Operant conditioning, 56, 57, 166
Oppositional defiant disorder (ODD), 137, 147, 148, 164, 166
Organizational Empowerment Scale, 99
Outpatient treatment, 23, 78, 84–87, 168, 169, 180, 189, 192, 258, 287, 456, 457
Over-the-counter medication, 353, 368
Overdose, 158, 262, 263

P
Panic attacks, 40, 161, 233–236, 239, 241, 243
Paranoia, 41, 273, 366
Parent Therapist Program, 171
Parietal lobe, 33
Parity, 20, 96, 377, 405, 426–429, 458
Parkinsonism, 89, 281, 344
Parkinson’s disease, 36, 350, 357
Paroxetine, 156, 243, 262, 353, 362
Partial hospitalization/day treatment, 169
Pathophysiology, 253, 350, 361
Patient Bill of Rights, 423
Patient Outcomes Research Team (PORT), 280, 283, 286, 425
Pavlov, Ivan, 56, 125
Pemoline, 146
Peptides, 36
Perception, 7, 40, 41, 83, 88, 158, 162, 167, 180, 240, 255, 269, 271, 368
Personal Empowerment Scale, 99
Personality disorders, 44, 65, 130, 167, 230, 244, 256, 258
Personality, theories of, 55–57, 227–229, 243, 246, 255
Pharmacodynamics, 282, 344, 345, 353
Pharmacokinetics, 140, 242, 282, 345, 368
Pharmacological therapy, 226
Pharmacology, 141
Phenobarbital, 158
Phobic anxiety, 364
Physical activities, 232
Physical development, 58
Physical health, 5, 6, 71, 128, 225, 230, 274, 348, 351, 355, 379, 380, 448. See also Somatic health
Piaget, Jean, 57, 59, 125
Pierce, C. M., 87
Pinel, Philippe, 78
Pituitary gland, 153, 239
Placebo effect, 10, 65, 70, 71, 88, 89, 147, 156–158, 162, 164, 166, 258, 261–265, 267, 280, 352, 354–356, 362
Planning Board, 24
Psychological development, 59, 230
Psychopharmacologic treatments, 15
Psychosis, 4, 7, 9, 40–43, 47, 54, 68, 69, 79, 146, 228, 254, 259, 274, 354, 356, 359, 374
Psychosocial risk factors, 63, 130, 252
Psychosocial treatments, 78, 141, 147, 148, 166, 226, 257, 266, 282, 283, 345, 355
Public health model, 3
Public Law 102-331, 95, 190

Q
Quality and consumers’ rights, 430
Quality assessment, 425

R
Racial and ethnic minorities, 39, 55, 67, 73, 80–82, 84–90, 94. See also African Americans; Asian/Pacific Islanders; Hispanic Americans; Native Americans/American Indians/Alaska Natives/Native Hawaiians (American Indians)
Randomized controlled trial, 10, 133, 189, 233
Range of treatments, 13, 15, 21, 64, 65, 102, 453
Rape, 50, 230, 237, 256
Raphe nuclei, 37

Reaching Across, 94
Recovery, 12, 14, 15, 18, 19, 22, 32, 55, 80, 92, 97–102, 128, 137, 154, 227, 261, 274, 275, 279, 280, 283, 284, 288–290, 349, 350, 353, 354, 366, 455
Reducing Risks for Mental Disorders, 62
Rehabilitation services, 79, 284, 286, 287, 293, 375, 406, 418
Mental Health: A Report of the Surgeon General

Remission, 71, 156, 161, 226, 249, 258, 261, 274, 283, 284, 349, 350, 353, 354, 356, 366
Report’s principal recommendation, 13, 21
Research methods, 10
Research volunteers, 21, 454
Rett’s disorder, 137
Risk factors and prevention in childhood and adolescent mental health, 129–136
Robert Wood Johnson Foundation, 190, 191, 289, 293, 295, 409
Rogers, Carl, 67
Residential treatment center (RTC), 170, 171

S
Social/health maintenance organization (S/HMO), 374
Schizoaffective disorder, 250, 270
Schizophrenia, 41–42, 227–228, 270–286, 365–367. See also Schizophrenia, demographic characteristics in; Schizophrenia in older adults; Schizophrenia, treatment of brain abnormalities in; causes, 276–279
comorbid medical illness and, 273–274
coping and self-monitoring, 284–285
diagnosis and cultural variations, 272–273
drug treatment of, 279–283
DSM-IV diagnostic criteria for, 272–273
epidemiology of, 273–274
genetic relationships in, 276
long-term outcomes in, 273–276, 284–285
natural history of, 274–276
onset of, 75–76
rehabilitation in, 274–275, 283–285
risk factors for, 276–278
services for, 279, 283–285, 286
symptoms and signs of, 41–42, 269–272, 276–278
Schizophrenia, demographic characteristics in
age, 275–276
culture, 272–273
gender, 275–276, 282
race, 272–273, 280–283
sociocultural status, 278
Schizophrenia in older adults, 365–367
causes of late-onset schizophrenia, 366–367
epidemiology of, 365
gender in, 367
natural history of, 366
treatment, 366, 367
Schizophrenia Patient Outcome Research Team, 88
Schizophrenia, treatment of, 279–285
ethropychopharmacology, 282–283
family intervention, 283
pharmacotherapy, 280–282
psychosocial, 279, 283–285
psychotherapy, 283
Schizophrenics Anonymous, 94
Schizophreniform disorder, 250
School system, 75, 169, 180, 409
Science base, 9, 21, 453
Sedatives, 237, 242
Seizures, 258–260, 264, 281, 353–354
Selective serotonin reuptake inhibitors (SSRIs), 69, 80, 89, 141, 147, 156–158, 162–164, 167, 239, 242–243, 252, 262–267, 343, 353
Self-efficacy, 189, 190, 229, 241
Self-esteem, 4, 6, 42, 94, 97, 131, 137, 170, 172, 177, 225, 228, 229, 237, 250, 285, 290, 339, 379
Self-medication, 167
Selye, Hans, 253
Separation anxiety disorder, 12, 16, 103, 137, 160–162, 234
Serious emotional disturbance, 172, 180, 184, 185, 190, 191
Serious mental illness (SMI), 46, 48
Serotonergic, 153, 265
Sertraline, 243, 262, 263, 353
Services interventions for children and adolescents, 168–179
case management, 172–175
Children and Youth Intensive Care Management (CYICM), 173
crisis services, 178–179
Family Centered Intensive Care Management (FCICM), 174
Family preservation programs, 175
Fostering Individualized Assistance Program (FIAP), 174
home-based services, 175–176
inpatient treatment, 171–172
multisystemic therapy (MST), 172, 175–176
newer community-based interventions, 172–178
outpatient treatment, 168–169
Parent Therapist Program, 171
partial hospitalization/day treatment, 169
Project ReEducation (ReEd), 170–171
residential treatment centers (RTCs), 169–170
serious emotional disturbance, defined, 172
therapeutic foster care, 176–177
team approaches, 174–175
therapeutic group homes, 177–178
treatment interventions, 168–172
Services, mental health, including service delivery and service system: general, 73–80
barriers to accessibility, 21
care settings, 74
community mental health movement, 79
community support movement, 80
de facto mental health system, four sectors of, 73
dementia, 78
and dual policies of community care and deinstitutionalization, 79
financing of, 73–74
Grob, Gerald N., 75
history of, in U.S., 75–80
hybridization of system complicates service to the most needy, 80
linguistically and culturally competent services, 81, 225
majority with diagnosable disorder do not receive treatment, 75
mental health services, in general, 73–80
mental hygiene movement, 78
moral treatment movement, 75–78
patterns of use, 75
recovery, 80
state care acts, 78
Services, mental health, including service delivery and service system: services and providers, 455–458
coercion, 457
delivery of state of the art treatments must be ensured, 455–456
entry into treatment must be facilitated, 457
financial barriers to treatment must be reduced, 457–458
first-line contacts, 457
gap between knowledge and actual practice, 456
geographical shortages, 455
inequity of coverage for mental and somatic illnesses, 457
justice systems, 457
new strategies needed, 456
respectful, evidence based, and reimbursable care must be ensured, 458
services and providers must be guaranteed, 455
shortages in cognitive behavioral and interpersonal therapy fields, 455
short supply of certain providers, services, 22, 455
treatment must be tailored to age, gender, race, and culture, 456
Services, mental health, including service delivery and service system: organization and financing of, 14, 19–20, 405–430
cost containment policies, 20
discriminatory policies in mental health financing, 20
financial barriers to, 20
insurance financing in, 20
managed care, 20
use of by U.S. population, 19

Services, mental health, including service delivery and service system: financing and managing, 418–426
coverage policy, fairness in, 420
goals for mental health coverage, 418
history of financing and roots of inequality, 418
insurance coverage patterns, 418–419
lifetime limits for somatic vs. mental illness, 420
limitations on coverage, 418
moral hazard and adverse selection, 420
traditional insurance and dynamics of cost containment, 419–420

Services, mental health, including service delivery and service system: managed care, 420–423
access, measurement system of, needed, 424
access to services, impact on, 424
and regulation, 423
carve-out managed behavioral health care, 421
cost controls in managed care, 423
coverage, percentages of, 422
health maintenance organizations (HMOs), 421
managed behavioral health care organizations (MBHOs), 421
managed care effects on service access and quality, 423–424
managed care plans, major types, 421
payer carve-outs and health plan subcontracts, 421
point-of-service plans (POS), 421
preferred provider organizations (PPOs), 421
quality assessment and quality indicators, 425
quality of care, impact on, 424–426
quality of care not provided incentives, 425

Services, mental health, including service delivery and service system: mental health service system in the U.S., 405–411
de facto mental health service system, four components of, 405–406
patterns of use, 408–409
public and private sectors, defined, 407–408
school system and, 409
structure of U.S. service system, 405–406
substantial majority of adults do not receive treatment, 408

Services, mental health, including service delivery and service system: parity, 426–428
benefit restrictions and, 426–427
gap widening between somatic and mental coverage, 427
legislative trends affecting, 427–428
Mental Health Parity Act, 427–428
minimal costs of parity laws, 428
state efforts for, 428
toward parity in mental health coverage, 426–428

Services, mental health, including service delivery and service system: service delivery for adults, 285–289
assertive community treatment, 286–287
case management, 286
comorbidity and, 288–289
for substance abuse and severe mental illness, 288–289
inpatient hospitalization and community alternatives for crisis care, 287–288
intervention for stressful life events, 232–233
overrepresentation of minorities in inpatient units, 288
psychosocial rehabilitation services, 287
recovery and, 288
substance abuse and, 288

Services, mental health, including service delivery and service system: supports and other services for adults, 289–295
consumer advocacy, 291
Index

consumer-operated programs, 290–291
consumer self-help, 289–290
discrimination against the mentally ill and, 292
family advocacy, 292
family self-help, 291–292
health coverage and barriers to treatment, 294
housing, 292–293
human services, 292–294
income, education, and employment, 293–294
integrating service systems, 295

Services, mental health, including service delivery and service system: service delivery and supports for children and adolescents, 179–193
Child and Adolescent Service System Program (CASSP), 190–191
Children’s Services Program (CSP), 191
culturally appropriate social support services, 186–187
effectiveness of systems of care, 191–193
families, redefinition of and new roles for, 188
family support, 188–189
family support groups, 189–190
Fort Bragg study, 191–192
integrated system model, 190–191
practical support, 190
private sector, 182–183
public sector, 183–184
public sector, managed care in, 185–186
Robert Wood Johnson Foundation, 190, 191, 289, 293, 295, 409
service systems and financing, 182–186
Stark County study, 192–193
support and assistance for families, 187–190
utilization, 179–182
utilization and culture, 181–182
utilization and early termination of treatment, 180
utilization and poverty, 181
utilization in relation to need, 180

Wraparound Milwaukee and, 185–186
Services, mental health, including service delivery and service system: service delivery for older adults, 370–378
adult day care centers and community care settings, 373–374
carved-in mental health services for older adults, 376–377
deinstitutionalization, 374
demographics of residence and, 370
ethnic diversity and, 371
financing services for older adults, 376
for severe and persistent mental disorders (SPMDs), 374–376
home vs. nursing home, 372–374
increased role of managed care, 376
Medicaid and, 376
nursing homes ill equipped to treat mental disorders, 374
outcomes under managed care, 377–378
preadmission screening, 374
primary care poorly equipped to treat chronic mental disorders, 372–373
public policy and managed care and, 370–371
research needed on cost effective models for treatment, 376
service settings and the New Landscape for Aging, 371–376
setting, role of, in independent functioning, 372

Services, mental health, including service delivery and service system: supports and other services for older adults, 378–380
abuse of older people and, 380
communities and social services, 380–381
education and health promotion, 379
families and caregivers, 379–380
support and self-help groups, 378–379
support for caregivers crucial, 378

Services demonstration projects
brief history of, 290
Child and Adolescent Service System Program (CASSP), 190
Children’s Services Program, 190–191
Fort Bragg study, 191–192
Mental Health: A Report of the Surgeon General

Robert Wood Johnson Foundation, 190, 191, 289, 293, 295, 409
Stark County study, 192–193
Severe and persistent mental disorder (SPMD), 374, 375, 377, 378
Severe and persistent mental illness (SPMI), 79, 289, 295, 415, 419
Sex, 43, 56, 60, 133, 135, 151, 176, 231, 236, 255–257. See also Gender
Sexual abuse, 231, 254–256
Sexual orientation, 22, 81, 155, 442, 456
Skinner, B. F., 56, 125
Sleep disturbances, 245, 350
Social factors, 13, 47, 48, 50–52, 100, 253, 274, 278
Social learning theory, 56, 57, 125
Social portfolio, 379
Social status, role of in mental health, 55, 81–82, 84, 91
Social support services, 181, 186
Sociopathy, 229
Somatic health, 6, 232–234, 272–275, 286, 427. See also Physical health
Somatization disorder, 230
Somatoform disorder, 44
Specialty mental health providers, 14, 101, 413
Specific phobia, 233–235
Spending for mental health services, 12, 19, 49, 174, 249, 405, 411–417, 429
Spirituality, role of, in mental health, 81, 82, 98, 99, 225, 232
St. John's wort, 70, 264–265
Stark County study, 192
State mental health agencies and efforts, 95, 96, 291, 417, 419, 442, 446–448
State-of-the-art treatments, 22, 455
Stigma, 3, 6–9, 12, 14, 16, 20–22, 73, 80, 84, 85, 87, 92, 96, 101, 103, 160, 180, 186, 188, 226, 227, 244, 257, 289, 291–294, 346, 349, 376, 379, 424, 429, 439, 440, 448, 449, 453, 454
Stimulants, 68, 69, 142, 145–150, 369
Substance abuse laws, 445, 446
Substance P, 36
Substance induced events, 233
Substantia nigra, 37
Suicide prevention, 159, 160, 244, 342, 351
Sulci, 33
Superego, 56, 229
Support groups, 189, 232, 292, 356, 378, 380
Supportive therapy, 158
Supreme Court, U.S., 21, 437, 439, 445, 448, 449
Surgeon General, U.S., 4, 23, 24, 160, 244, 342
Synapses, 33, 36, 38–39, 50, 58, 61, 69, 262

T

Tardive dyskinesia, 147, 268, 281, 282, 344, 345, 367
Team approaches, 174
Temperament, 12, 31, 57, 64, 125, 127, 129–132, 255
Temporal lobe, 277, 347, 362
Therapeutic foster care, 171, 172, 176–178, 184
Therapeutic group home, 172, 177, 178
They Help Each Other Spiritually (THEOS), 379
Tourette's disorder, 129, 137, 236
Trauma, 18, 51, 52, 130, 159, 161, 170, 225, 230, 231, 237, 254, 256, 289

486
Treatment for children and adolescents, 155–160, 168

Treatment, in general, 64–73
  attitudinal barriers, 73
  barriers to seeking help, 72–73
  behavior therapy, 66–67
  cognitive-behavioral therapy, 67
  complementary and alternative treatments, 70
  demographic barriers, 73
  efficacy-effectiveness gap, 72
  existential, experiential, or Gestalt therapy, 67
  failure to seek, due to stigma, 8
  financial barriers, 73
  Freud and psychoanalysis, 66
  group psychotherapy, 65
  humanistic therapy, 67
  informal social supports now preferred, 8
  interpersonal therapy, 66
  mechanism of action, defined, 68–70
  neurotransmitter function, 68–69
  organizational barriers, 73
  pharmacological therapies, 68–70
  placebo and, 65, 70–71
  psychodynamic therapy, 66
  psychotherapy, defined, 65
  rational drug design, 68
  tailored treatment, 22–23

Treatment interventions, 19, 128, 139, 140, 168, 176, 381

Treatment systems, 6

Tricyclic antidepressants (TCAs), 69, 89, 142, 147, 156, 158, 162, 167, 242, 243, 262–265, 267, 352, 353

Trust, 21, 60, 87, 91, 437, 439, 449

Twins, 54, 61, 63, 162, 163, 165, 256, 276

U

U.S. Office of Technology Assessment, 180
Unclaimed Children, 96
Uncontrolled studies, 10, 164, 169–172, 174, 177–179, 191, 268

Undertreatment, 257, 348, 423, 426, 458
Unemployment, 64, 272, 285, 292–294
Unipolar depression, 267, 353, 354

V

Valproate, 142, 157
Vascular, 352, 354, 358
Venlafaxine, 243, 263, 267, 353
Ventral tegmental area, 37
Verapamil, 268
Violence, 7, 8, 64, 130, 165, 231, 232, 288, 439
Visual hallucinations, 249, 271
Vitamin E, 342, 357, 360, 361
Volunteers, 21, 454

W

Waiver of confidentiality, 442, 443
Watson, J. B., 56, 125
Well-Being Project, 99
Well-Established Psychosocial Interventions, 140
White matter, 35, 352
World Health Organization, 4, 45, 284, 411
World Bank, 4, 411
Wraparound process, 173, 174, 179, 183, 185–186, 455
Wraparound Milwaukee, 185–186

Y

Youth Emergency Services (YES), 179, 438